[go: up one dir, main page]

DE60032949D1 - Immuntherapeutische methoden und moleküle - Google Patents

Immuntherapeutische methoden und moleküle

Info

Publication number
DE60032949D1
DE60032949D1 DE60032949T DE60032949T DE60032949D1 DE 60032949 D1 DE60032949 D1 DE 60032949D1 DE 60032949 T DE60032949 T DE 60032949T DE 60032949 T DE60032949 T DE 60032949T DE 60032949 D1 DE60032949 D1 DE 60032949D1
Authority
DE
Germany
Prior art keywords
immunotherapic
molecules
methods
immunotherapic methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60032949T
Other languages
English (en)
Other versions
DE60032949T2 (de
Inventor
Hans Josef Stauss
Persis J Amrolia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Application granted granted Critical
Publication of DE60032949D1 publication Critical patent/DE60032949D1/de
Publication of DE60032949T2 publication Critical patent/DE60032949T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70589—CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4252—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60032949T 2000-11-30 2000-11-30 Immuntherapeutische methoden und moleküle Expired - Fee Related DE60032949T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/004566 WO2002044207A1 (en) 2000-11-30 2000-11-30 Immunotherapeutic methods and molecules

Publications (2)

Publication Number Publication Date
DE60032949D1 true DE60032949D1 (de) 2007-02-22
DE60032949T2 DE60032949T2 (de) 2007-10-25

Family

ID=9886462

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032949T Expired - Fee Related DE60032949T2 (de) 2000-11-30 2000-11-30 Immuntherapeutische methoden und moleküle

Country Status (7)

Country Link
US (1) US20030103946A1 (de)
EP (1) EP1339745B1 (de)
AU (1) AU2001216472A1 (de)
CA (1) CA2436903A1 (de)
DE (1) DE60032949T2 (de)
ES (1) ES2282148T3 (de)
WO (1) WO2002044207A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2220113B1 (de) * 2007-12-03 2015-10-21 Isis Innovation Limited Ein Verfahren zur Identifizierung eines T-Zell-Rezeptor (TCR) zum Schutz gegen eine Krankheit
GB0917094D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
EP3917313A4 (de) * 2019-02-01 2023-02-08 Actinium Pharmaceuticals, Inc. Gegen cd45 gerichtete moleküle und deren derivate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) * 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
WO1992013887A1 (en) * 1991-02-07 1992-08-20 The Victoria University Of Manchester New cell adhesion peptides
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
AU751340B2 (en) * 1998-07-10 2002-08-15 Fuso Pharmaceutical Industries, Ltd. Antibody against protein tyrosine phosphatase intracellular domains
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions

Also Published As

Publication number Publication date
WO2002044207A1 (en) 2002-06-06
EP1339745A1 (de) 2003-09-03
US20030103946A1 (en) 2003-06-05
AU2001216472A1 (en) 2002-06-11
EP1339745B1 (de) 2007-01-10
DE60032949T2 (de) 2007-10-25
CA2436903A1 (en) 2002-06-06
ES2282148T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
DE50112013D1 (de) Deodorantien und antiperspirantien
ATE306318T1 (de) Entschwefelung und hierfür geeignetes sorbens
DE60139930D1 (de) Desinfizieruns- und desodorierungsverfahren
DE60102851D1 (de) Paneelanordnung und Verbindungsmittel
NO20032587L (no) ABCA-1 eleverende forbindelser
DE60143095D1 (de) Trokar und trokarsystem
FI20001907L (fi) Hitsausjärjestely ja -menetelmä
EP1412378A4 (de) Aptamere und antiaptamere
DE60119028D1 (de) Zugangspunkt und Authentifizierungsverfahren dafür
FI20001837L (fi) Autentikointi
ATE391531T1 (de) Schweisshemmende mittel
DE50103327D1 (de) Mikromechanisches bauelement und entsprechendes herstellungsverfahren
DE60132139D1 (de) Lautsprecher und Verfahren zum Zusammenbauen des Lautsprechers
DE60023103D1 (de) Lüfter und dessen Herstellungverfahren
DE50114713D1 (de) Mikrostrukturbauelement
DK1322597T3 (da) Fremgangsmåde og intermediære
DE60038110D1 (de) Dämpfer und herstellungsmethode dafür
EP1333910A4 (de) Elektrophoresevorrichtung und -verfahren
NO20030276L (no) Fremgangsmåte
DE60142600D1 (de) Entwicklungsverfahren und -vorrichtung
FI20000292A0 (fi) Testausjärjestely ja testausmenetelmä
DE60141890D1 (de) Biegeverfahren und biegevorrichtung
DE60134018D1 (de) Chtung zur anwendung damit
DE60134222D1 (de) Biegeverfahren und Biegevorrichtung
NO20024617D0 (no) Aryl- og heteroarylsulfonater

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: STAUSS, HANS JOSEF, LONDON W12 0NN, GB

Inventor name: AMROLIA, PERSIS J., LONDON W12 0NN, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee